152 related articles for article (PubMed ID: 35788723)
21. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.
Chi AS; Tarapore RS; Hall MD; Shonka N; Gardner S; Umemura Y; Sumrall A; Khatib Z; Mueller S; Kline C; Zaky W; Khatua S; Weathers SP; Odia Y; Niazi TN; Daghistani D; Cherrick I; Korones D; Karajannis MA; Kong XT; Minturn J; Waanders A; Arillaga-Romany I; Batchelor T; Wen PY; Merdinger K; Schalop L; Stogniew M; Allen JE; Oster W; Mehta MP
J Neurooncol; 2019 Oct; 145(1):97-105. PubMed ID: 31456142
[TBL] [Abstract][Full Text] [Related]
22. Significance of H3K27M mutation with specific histomorphological features and associated molecular alterations in pediatric high-grade glial tumors.
Bozkurt SU; Dagcinar A; Tanrikulu B; Comunoglu N; Meydan BC; Ozek M; Oz B
Childs Nerv Syst; 2018 Jan; 34(1):107-116. PubMed ID: 29063957
[TBL] [Abstract][Full Text] [Related]
23. Diffusion Characteristics of Pediatric Diffuse Midline Gliomas with Histone H3-K27M Mutation Using Apparent Diffusion Coefficient Histogram Analysis.
Aboian MS; Tong E; Solomon DA; Kline C; Gautam A; Vardapetyan A; Tamrazi B; Li Y; Jordan CD; Felton E; Weinberg B; Braunstein S; Mueller S; Cha S
AJNR Am J Neuroradiol; 2019 Nov; 40(11):1804-1810. PubMed ID: 31694820
[TBL] [Abstract][Full Text] [Related]
24. Histone H3 wild-type DIPG/DMG overexpressing EZHIP extend the spectrum diffuse midline gliomas with PRC2 inhibition beyond H3-K27M mutation.
Castel D; Kergrohen T; Tauziède-Espariat A; Mackay A; Ghermaoui S; Lechapt E; Pfister SM; Kramm CM; Boddaert N; Blauwblomme T; Puget S; Beccaria K; Jones C; Jones DTW; Varlet P; Grill J; Debily MA
Acta Neuropathol; 2020 Jun; 139(6):1109-1113. PubMed ID: 32193787
[No Abstract] [Full Text] [Related]
25. The prognostic significance of HIST1H3B/C and H3F3A K27M mutations in diffuse midline gliomas is influenced by patient age.
Vuong HG; Ngo TNM; Le HT; Dunn IF
J Neurooncol; 2022 Jul; 158(3):405-412. PubMed ID: 35606633
[TBL] [Abstract][Full Text] [Related]
26. H3F3A mutant allele specific imbalance in an aggressive subtype of diffuse midline glioma, H3 K27M-mutant.
Maeda S; Ohka F; Okuno Y; Aoki K; Motomura K; Takeuchi K; Kusakari H; Yanagisawa N; Sato S; Yamaguchi J; Tanahashi K; Hirano M; Kato A; Shimizu H; Kitano Y; Yamazaki S; Yamashita S; Takeshima H; Shinjo K; Kondo Y; Wakabayashi T; Natsume A
Acta Neuropathol Commun; 2020 Feb; 8(1):8. PubMed ID: 32019606
[TBL] [Abstract][Full Text] [Related]
27. Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas.
Schreck KC; Ranjan S; Skorupan N; Bettegowda C; Eberhart CG; Ames HM; Holdhoff M
J Neurooncol; 2019 May; 143(1):87-93. PubMed ID: 30864101
[TBL] [Abstract][Full Text] [Related]
28. Diffuse Midline Gliomas With Histone H3 K27M Mutation in Adults and Children: A Retrospective Series of 164 Cases.
Zheng L; Gong J; Yu T; Zou Y; Zhang M; Nie L; Chen X; Yue Q; Liu Y; Mao Q; Zhou Q; Chen N
Am J Surg Pathol; 2022 Jun; 46(6):863-871. PubMed ID: 35416795
[TBL] [Abstract][Full Text] [Related]
29. Gliomas in children and adolescents: investigation of molecular alterations with a potential prognostic and therapeutic impact.
Cabral de Carvalho Corrêa D; Tesser-Gamba F; Dias Oliveira I; Saba da Silva N; Capellano AM; de Seixas Alves MT; Dastoli PA; Cavalheiro S; Caminada de Toledo SR
J Cancer Res Clin Oncol; 2022 Jan; 148(1):107-119. PubMed ID: 34626238
[TBL] [Abstract][Full Text] [Related]
30. H3.3-G34 mutations impair DNA repair and promote cGAS/STING-mediated immune responses in pediatric high-grade glioma models.
Haase S; Banerjee K; Mujeeb AA; Hartlage CS; Núñez FM; Núñez FJ; Alghamri MS; Kadiyala P; Carney S; Barissi MN; Taher AW; Brumley EK; Thompson S; Dreyer JT; Alindogan CT; Garcia-Fabiani MB; Comba A; Venneti S; Ravikumar V; Koschmann C; Carcaboso ÁM; Vinci M; Rao A; Yu JS; Lowenstein PR; Castro MG
J Clin Invest; 2022 Nov; 132(22):. PubMed ID: 36125896
[TBL] [Abstract][Full Text] [Related]
31. Co-occurrence of histone H3 K27M and BRAF V600E mutations in paediatric midline grade I ganglioglioma.
Pagès M; Beccaria K; Boddaert N; Saffroy R; Besnard A; Castel D; Fina F; Barets D; Barret E; Lacroix L; Bielle F; Andreiuolo F; Tauziède-Espariat A; Figarella-Branger D; Puget S; Grill J; Chrétien F; Varlet P
Brain Pathol; 2018 Jan; 28(1):103-111. PubMed ID: 27984673
[TBL] [Abstract][Full Text] [Related]
32. Diffuse Midline Gliomas with Histone H3-K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations.
Solomon DA; Wood MD; Tihan T; Bollen AW; Gupta N; Phillips JJ; Perry A
Brain Pathol; 2016 Sep; 26(5):569-80. PubMed ID: 26517431
[TBL] [Abstract][Full Text] [Related]
33. MRI and Molecular Characterization of Pediatric High-Grade Midline Thalamic Gliomas: The HERBY Phase II Trial.
Rodriguez D; Calmon R; Aliaga ES; Warren D; Warmuth-Metz M; Jones C; Mackay A; Varlet P; Le Deley MC; Hargrave D; Cañete A; Massimino M; Azizi AA; Saran F; Zahlmann G; Garcia J; Vassal G; Grill J; Peet A; Dineen RA; Morgan PS; Jaspan T
Radiology; 2022 Jul; 304(1):174-182. PubMed ID: 35412366
[TBL] [Abstract][Full Text] [Related]
34. Diffusion and perfusion imaging biomarkers of H3 K27M mutation status in diffuse midline gliomas.
Kathrani N; Chauhan RS; Kotwal A; Kulanthaivelu K; Bhat MD; Saini J; Prasad C; Chakrabarti D; Santosh V; Uppar AM; Srinivas D
Neuroradiology; 2022 Aug; 64(8):1519-1528. PubMed ID: 35083503
[TBL] [Abstract][Full Text] [Related]
35. Adult diffuse midline gliomas H3 K27-altered: review of a redefined entity.
López-Pérez CA; Franco-Mojica X; Villanueva-Gaona R; Díaz-Alba A; Rodríguez-Florido MA; Navarro VG
J Neurooncol; 2022 Jul; 158(3):369-378. PubMed ID: 35567713
[TBL] [Abstract][Full Text] [Related]
36. Pediatric Diffuse Midline Gliomas H3 K27M-Mutant and Non-Histone Mutant Midline High-Grade Gliomas in Neurofibromatosis Type 1 in Comparison With Non-Syndromic Children: A Single-Center Pilot Study.
Garibotto F; Madia F; Milanaccio C; Verrico A; Piccardo A; Tortora D; Piatelli G; Diana MC; Capra V; Garrè ML; Rossi A; Morana G
Front Oncol; 2020; 10():795. PubMed ID: 32582540
[No Abstract] [Full Text] [Related]
37. The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location.
Liu I; Jiang L; Samuelsson ER; Marco Salas S; Beck A; Hack OA; Jeong D; Shaw ML; Englinger B; LaBelle J; Mire HM; Madlener S; Mayr L; Quezada MA; Trissal M; Panditharatna E; Ernst KJ; Vogelzang J; Gatesman TA; Halbert ME; Palova H; Pokorna P; Sterba J; Slaby O; Geyeregger R; Diaz A; Findlay IJ; Dun MD; Resnick A; Suvà ML; Jones DTW; Agnihotri S; Svedlund J; Koschmann C; Haberler C; Czech T; Slavc I; Cotter JA; Ligon KL; Alexandrescu S; Yung WKA; Arrillaga-Romany I; Gojo J; Monje M; Nilsson M; Filbin MG
Nat Genet; 2022 Dec; 54(12):1881-1894. PubMed ID: 36471067
[TBL] [Abstract][Full Text] [Related]
38. Deep Learning for Noninvasive Assessment of H3 K27M Mutation Status in Diffuse Midline Gliomas Using MR Imaging.
Li J; Zhang P; Qu L; Sun T; Duan Y; Wu M; Weng J; Li Z; Gong X; Liu X; Wang Y; Jia W; Su X; Yue Q; Li J; Zhang Z; Barkhof F; Huang RY; Chang K; Sair H; Ye C; Zhang L; Zhuo Z; Liu Y
J Magn Reson Imaging; 2023 Sep; 58(3):850-861. PubMed ID: 36692205
[TBL] [Abstract][Full Text] [Related]
39. Slow-Growing Thalamic Glioma with Histone H3 Lysine 27-to-Methionine Mutation: 3-Year Follow-Up Before Surgical Intervention.
Chanchotisatien A; Pan J; Du Z; Qiu T; Yu J; Chu S
World Neurosurg; 2019 Jul; 127():266-268. PubMed ID: 30981797
[TBL] [Abstract][Full Text] [Related]
40. A tumor suppressor role for EZH2 in diffuse midline glioma pathogenesis.
Dhar S; Gadd S; Patel P; Vaynshteyn J; Raju GP; Hashizume R; Brat DJ; Becher OJ
Acta Neuropathol Commun; 2022 Apr; 10(1):47. PubMed ID: 35395831
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
